DONECEPT 10 mg. 30 tablets
Donepezil is a medicine that inhibits an enzyme in the brain tissue of human and thus has a beneficial effect on Alzheimer's disease.
Danetsept apply for the symptomatic treatment of mild to moderate forms of dementia Aytshaymer.
BEFORE YOU TAKE DONECEPT
Donecept not apply to:
- Hypersensitivity to product, piperidine derivatives or any of the excipients;
Upon application of this product note the following:
Donetsept treatment should be performed by a physician experienced in the diagnosis and treatment of Alzheimer's dementia. Diagnosis should be made according to generally accepted principles. Treatment should be initiated only provided a caregiver who will regularly monitor drug intake. It continues until benefit to the patient. It is necessary to make periodic reassessment of the clinical effect of treatment. In the absence of curative effect should be considered interruption.
No data on the influence of severe dementia of the Alzheimer's disease, other types of dementia or other types of severe memory disorders
As a cholinesterase inhibitor Donecept is likely to intensify the effect of suktsinolholinovite muscle relaxation during anesthesia
Because the mechanism of action, this group of drugs can slow the heart rate. In patients with 'syndrome sick sinus "or other supraventricular cardiac conduction as sinuatrialen block and atrioventricular block Donetsept should be used with caution because of the risk of deepening the conduction abnormalities.
The product is used with caution in patients with ulcer in the past or those taking NSAIDs. No evidence of increased incidence of bleeding in the gastrointestinal tract or the onset of peptic ulcer.
The drug may cause difficulty in urination, although this was not observed in the treatment with Donecept
Cholinomimetics can cause generalized seizures that other old may be a symptom of Alzheimer's disease.
It is possible exacerbation or unlock extrapyramidal symptoms with involuntary limb movements, language, mimic muscles.
The product should be used with caution in patients with asthma or obstructive pulmonary disease because of their cholinomimetic action.
The administration of the product together with other inhibitors of acetylcholinesterase, agonists or antagonists of the cholinergic system should be avoided
Severe hepatic insufficiency
There is no data on the use of Donecept in patients with severe hepatic insufficiency
The product contains lactose, which makes it unsuitable for patients with lactase deficiency, galactosemia or glucose / galactose malabsorption syndrome.
Application of Donetsept and intake of foods and drinks
There is no need for a special diet during treatment with this product.
Before taking any medicine, consult your doctor. It is not known harm to the unborn research on animals. Donecept should not be administered to pregnant women.
Before taking any medicine, consult your doctor.
It is not known whether the product is excreted in human milk, and therefore breast-feeding should be discontinued during treatment.
Driving and using machines
Alzheimer's dementia may impair the ability to drive or operate machinery. Donetsept can cause fatigue, dizziness and muscle cramps usually at the beginning of treatment or when increasing the dose.
Your doctor should carefully consider whether patients suffering from Alzheimer's can not drive or operate machinery.
HOW TO USE DONECEPT
Always take Donecept after instructions of the doctor.
Adults / Elderly
The treatment starts with a dose of 5 mg once daily. The product should not be taken at bedtime. The dose of 5 mg should be administered at least one month to achieve steady and assessment of therapeutic response. Thereafter, the dosage can be increased to 10 mg per day in one dose. The maximum recommended dose is 10 mg daily.
Upon discontinuation of treatment, a gradual disappearance of the effect of the product. No evidence of deterioration after abrupt discontinuation of therapy.
Patients with kidney and liver failure
The dosing schedule is as above because this condition does not affect the release of the product. Due to the possibility of increasing the concentration of Donetsept with mild to moderate hepatic impairment, dose escalation should be done depending on tolerability. There are no data on use in patients with severe hepatic insufficiency.
Not recommended for use in children Donetsept.
POSSIBLE SIDE EFFECTS
Infections and infestations:
Common - cold
Metabolism and nutrition disorders:
Common - Anorexia
Common - hallucinations, anxiety, aggressive behavior
Nervous system disorders:
Common - syncope, dizziness, insomnia ,,
Uncommon - epileptic seizures
Rare - extrapyramidal symptoms
Uncommon - slow heartbeat
Rare - sinuatrialen block, atrioventricular block
Common - diarrhea, vomiting, nausea, abdominal disorders
Uncommon - gastrointestinal bleeding, gastric and duodenal ulcers
Rare. hepatic impairment, incl. hepatitis
Skin and subcutaneous tissue disorders:
Common - rash, itching
Disorders Musculoskeletal and connective tissue disorders:
Common - muscle cramps
Renal and urinary:
Common - incontinence
Common - headache, fatigue, pain
Minimal increases in serum concentrations of muscle creatine kinase
Injury, poisoning resulting interventions:
Common - accidents
The active ingredient is donepezil hydrochloride.
The other ingredients are lactose monohydrate, cellulose microcrystalline, corn starch, magnesium stearate
Composition of tablet coated tablet 5 mg: Opadry White, polyvinyl alcohol, titanium dioxide, macrogol 3350, talc
Composition of tablet coated tablets 10 mg: Opadry yellow, polyvinyl alcohol, titanium dioxide, macrogol 2250, talc.
One tablet contains 5 or 10 mg of donepezil hydrochloride.